Introduction {#s1}
============

The Global Burden of Disease Study (GBD), coordinated by the Institute for Health Metrics and Evaluation (IHME), has emerged as the largest systematic, data-driven effort to quantify the magnitude of health loss from all major diseases and injuries. GBD estimates have influenced global public health research, policy, education, and action on a wide range of diseases and risk factors. Examples of these data-driven impacts are the initiation of free short-term depression therapy in Australia, restructuring of health insurance coverage to align with major causes of disease in Mexico, and construction of new roads and retraining of police to address the high burden of traffic injuries in Iran ([@c136]).

IHME's comparative risk assessments have focused attention on the magnitude of the global burden of disease caused by air pollution since 2010, alongside other major health risk factors such as smoking, diet, and obesity ([@c158]). These estimates placed reduction of exposure to ambient and household air pollution squarely on the global health agenda, eliciting high-level government responses in China and India, and provide key metrics for several Sustainable Development Goals (SDGs). In its 2017 publication, the *Lancet* Commission on Pollution and Health used 2015 GBD data to calculate that the combined pollution of air, water, and soil by chemicals was responsible for 268 million disability-adjusted life-years (DALYs) and 9 million premature deaths each year---more than 3 times the total annual deaths caused by HIV/AIDS, tuberculosis, and malaria---with the greatest burden in low- and middle-income countries (LMICs) ([@c86]). The 2017 GBD study estimated that specific environmental health (EH) risk factors accounted for 8.32 million deaths and 308 million DALYs ([@c139]). Meanwhile, the World Health Organization (WHO), which had been making its own estimates of the global burden of disease parallel to IHME, produced data for environmental impacts in 2017 that were in a similar range ([@c121]); shortly thereafter, WHO and IHME signed an agreement to collaborate, jointly making all GBD estimates going forward.

Although large, these estimates capture only a fraction of the burden associated with the limited EH risk factors included in the GBD analysis: certain air pollutants, water, lead, and occupational exposures. In response, the Global Burden of Disease--Pollution and Health Initiative (GBD-PHI) was formed. This new initiative aims to work with the GBD to improve and expand estimates of the global burden of disease attributable to an expanded set of EH risk factors, including current and projected climate-related disease burden. Here, we provide an overview of the GBD to the EH community and then articulate some of the ideas, challenges, and opportunities associated with the GBD-PHI, which were discussed at an inaugural workshop in March 2018 ([@c66]) and have been the subject of ongoing discussions. We outline an ambitious research agenda for the GBD-PHI, first by providing an overview of GBD methods for estimating exposure to risk factors and the associated burden, followed by a focus on air pollution and lead as two case studies. We then discuss the challenges and opportunities associated with grading the evidence for causality and combining these considerations to rank and prioritize EH risk factors for inclusion in the GBD. Finally, we discuss neurotoxicants and endocrine disrupting chemicals (EDCs) as examples of likely high-priority classes of candidates for inclusion in the GBD, and we consider the special challenges of estimating the burden of disease and death related to climate change. A summary of the proposed research agenda and recommendations is provided in Appendix 1.

As stated in the GBD Protocol, "an uncertain estimate ... is preferable to no estimate because no estimate is often taken to mean no health loss from that condition" ([@c73]). Ultimately, by more fully documenting the current and anticipated impacts and risks of EH exposures on the burden of disease and death at the subnational, national, and international scales, countries will be better able to prioritize pollution control investments that promote long-term stability, growth, and prosperity.

GBD Overview and Existing EH Risk Factors {#s1.1}
-----------------------------------------

A full description of the GBD, GBD methods, and the most recent assessment of risk factors and associated burden for 195 countries and territories can be found in recent publications and associated appendices ([@c76]; [@c84]; [@c105]; [@c124]; [@c139]). Briefly, the GBD is coordinated by the IHME with the assistance of a network of more than 3,600 researchers in more than 145 countries. Using a comparative risk assessment approach, it organizes behavioral, environmental, occupational, and metabolic risk factors into five hierarchical levels. Level 0 includes the aggregated estimates for all risk factors combined. Level 1 includes three risk groups: *a*) environmental and occupational risks, *b*) metabolic risks, and *c*) behavioral risks. Each subsequent level includes more-detailed risk factors that are nested within the broader category above it ([Figure 1](#f1){ref-type="fig"}).

![Global Burden of Disease Study (GBD) risk factor hierarchy (adapted from [@c139]).](ehp-127-105001-g001){#f1}

Each risk factor is associated with one or more outcomes, and each combination of risk factor and outcome is referred to as a risk--outcome pair. Risk--outcome pairs are assessed for inclusion based primarily on two factors: *a*) the strength of evidence for a causal association between the risk and outcome, and, *b*) the feasibility of developing the necessary globally complete estimates of exposure levels. The process for assessing causal evidence focuses on identifying, screening, rating, and analyzing epidemiological studies, concluding with a weight of evidence determination following the World Cancer Research Fund criteria ([@c163]); the feasibility of estimating exposures is assessed based on available data, predictive covariates, and analytical methods. Risk--outcome pairs that are judged to meet the above criteria are presented for final review for approval by the GBD Scientific Council composed of subject-matter experts ([@c74]).

To calculate the attributable burden for each risk--outcome pair, the GBD requires for all locations: *a*) a burden estimate for the outcome \[e.g., number of deaths, years of life lost (YLL), and DALYs\]; *b*) spatially and temporally resolved exposure estimates for the risk factor; *c*) the counterfactual or theoretical minimum risk exposure level (TMREL); and *d*) the relative risk (i.e., exposure--response relationship) for the outcome, relative to the TMREL. The population attributable fraction (PAF) is defined as the proportion of the outcome, for a given population and year, that would be eliminated if the risk factor were reduced to the TMREL, and it is calculated from the last three of the aforementioned inputs. Risk-attributable disease burden is estimated for each risk--outcome pair by age group, sex, and location. GBD locations are arranged in a hierarchy: in [@c105], 195 countries and territories are nested within 21 regions, which in turn, are within 7 super-regions. Subnational estimates are made for countries with populations larger than 200 million as well as a select set of other countries.

To calculate years lived with disability (YLDs), GBD employs disability weights to quantify the severity of the health loss associated with different health states. Beginning in GBD 2010, the assignment of disability weights has involved an iterative ranking process whereby members of the general public are given descriptions of sequelae from two health states using nonclinical terminology and asked to rate which set of sequelae connotes a healthier individual. Results are analyzed to assess agreement between participants on pairings and then weights are generated on a scale from 0 to 1, where 0 indicates no health loss, and 1 indicates total health loss (i.e., equivalent to death) ([@c60]; [@c127]). In [@c105], disability weights were estimated for 234 unique health states ([@c139]).

The GBD uses a number of approaches to deal with complex statistical challenges, such as the incorporation of data that are uneven in uncertainty and distribution within time intervals, vary across time intervals, are prone to gaps in the data sequence over time, or that follow nonlinear trends. Specific examples and detailed explanations are provided in the appendices of the most recent publication ([@c139]).

In the most recent iteration, 84 behavioral, environmental/occupational, and metabolic risks or risk groups were evaluated, and burden was estimated for 476 risk--outcome pairs. The specific EH risk factors included in this assessment were unsafe water, sanitation, and handwashing; air pollution \[ambient ozone and fine particulate matter (${PM}_{2.5}$), and household ${PM}_{2.5}$\]; residential radon; lead; and occupational exposures to carcinogens (asbestos, arsenic, benzene, beryllium, cadmium, chromium, diesel exhaust, formaldehyde, nickel, polycyclic aromatic hydrocarbons, silica, sulphuric acid, trichloroethylene), as well as occupational asthmagens, particulate matter (PM)/gases, noise, injuries, and ergonomic factors. These EH risk factors were estimated to contribute to 8.32 million deaths and 308 million DALYs in 2017, in comparison with 8.15 million deaths and 345 million DALYs in 2007 ([@c139]). Given that most EH risk--outcome pairs cannot be assessed by randomized controlled trials (RCTs), the hierarchy of evidence involves assessing and weighing the results of prospective observational cohort and case--control studies that meet quality control standards ([Table 1](#t1){ref-type="table"}).

###### 

Summary of epidemiological evidence used to determine risk--outcome relationships for unsafe water, air pollution, radon, and lead in the Global Burden of Disease Study (GBD) 2017 (adapted from [@c139]).

Table 1 lists risk factor and outcomes in the first and second columns, respectively; the corresponding number of RCTs, number of prospective observational studies, and number of case-control studies are listed in the other columns.

  Risk factor                                                              Outcome                                            Study type        
  ------------------------------------------------------------------------ -------------------------------------------------- ------------ ---- ----
  Unsafe water, sanitation, and handwashing                                                                                                     
   Unsafe water source -- chlorination or solar (point of use treatment)   Diarrheal diseases                                 25           6    
   Unsafe water source -- piped                                            Diarrheal diseases                                 1            9    
   Unsafe water source -- filter                                           Diarrheal diseases                                 11           2    
   Unsafe water source -- improved water                                   Diarrheal diseases                                 0            5    
   Unsafe sanitation -- piped                                              Diarrheal diseases                                 0            7    
   Unsafe sanitation -- improved sanitation                                Diarrheal diseases                                 1            11   
   No access to handwashing facility                                       Diarrheal diseases                                 19           0    
   No access to handwashing facility                                       Lower respiratory infections                       8            11   
  Air pollution: Particulate matter pollution                                                                                                   
   Ambient particulate matter pollution                                    Lower respiratory infections                       0            17   
   Ambient particulate matter pollution                                    Tracheal, bronchus, and lung cancer                0            30   
   Ambient particulate matter pollution                                    Ischemic heart disease                             0            16   
   Ambient particulate matter pollution                                    Ischemic stroke                                    0            30   
   Ambient particulate matter pollution                                    Intracerebral hemorrhage                           0            30   
   Ambient particulate matter pollution                                    Subarachnoid hemorrhage                            0            30   
   Ambient particulate matter pollution                                    Chronic obstructive pulmonary disease              0            12   
   Ambient particulate matter pollution                                    Diabetes mellitus type 2                           0            8    
   Household air pollution from solid fuels                                Lower respiratory infections                       2            8    17
   Household air pollution from solid fuels                                Tracheal, bronchus, and lung cancer                0            0    28
   Household air pollution from solid fuels                                Ischemic heart disease                             0            2    2
   Household air pollution from solid fuels                                Ischemic stroke                                    0            1    
   Household air pollution from solid fuels                                Intracerebral hemorrhage                           0            1    
   Household air pollution from solid fuels                                Subarachnoid hemorrhage                            0            1    
   Household air pollution from solid fuels                                Chronic obstructive pulmonary disease              0            0    11
   Household air pollution from solid fuels                                Diabetes mellitus type 2                           0            1    
   Household air pollution from solid fuels                                Cataract                                           0            0    8
   Ambient ozone pollution                                                 Chronic obstructive pulmonary disease              0            3    
  Other environmental risks                                                                                                                     
   Residential radon                                                       Tracheal, bronchus, and lung cancer                0            1    29
   Lead exposure                                                           Idiopathic developmental intellectual disability   0            8    
   Lead exposure                                                           Systolic blood pressure                            0            3    1

Note: See original table for primary references. (Adapted from Appendix 1, Table 1 [@c139]).

Discussion {#s2}
==========

In the following discussion, we have deliberately chosen to focus on environmental pollutants to which the general population is exposed, using air pollution and lead as case studies of EH risk factors currently incorporated in the GBD, as well as climate change. In so doing, we acknowledge that the communicable diseases associated with sanitation, hygiene, and unsafe water account for a large proportion of the GBD associated with the environment and remain a major global environmental health challenge for much of the world. Similarly, we acknowledge that occupational hazards exist throughout the world. However, we argue that these risk factors are relatively well-established and recognized, whereas, by comparison, environmental pollutants and their impacts on populations remain relatively under-recognized, with the vast majority entirely unaccounted for.

Case Studies of Current EH Risk Factors in the GBD {#s2.1}
--------------------------------------------------

### Air pollution. {#s2.1.1}

The GBD has included estimates of disease and premature death due to air pollution since 1990; major urban areas were included in GBD 2000 and extended to the global population in GBD 2010 ([@c96]; [@c106]), when the current methods for estimating exposure and risk were introduced. These innovations produced estimates of burden that ranked air pollution exposure as one of the leading risk factors for premature mortality globally. With each update, the GBD incorporates new exposure and epidemiological data and methods to improve the quality and scope of its estimates. The GBD's partnership with the Health Effects Institute (HEI), among other collaborators, has been instrumental in this work.

The GBD currently estimates the burden attributable to air pollution exposure for three categories: ambient ${PM}_{2.5}$, ambient ozone, and ${PM}_{2.5}$ from household use of solid fuels for cooking ([@c51]; [@c64]). These three risk factors are globally measurable exposures that represent largely (though not entirely) independent sources contributing to the disease burden attributable to air pollution. Ambient ${PM}_{2.5}$ is the most robust predictor of mortality in studies of long-term exposure to air pollution. Ozone, a gas produced in photochemical atmospheric reactions of precursor emissions, is independently (from ${PM}_{2.5}$) associated with respiratory disease ([@c103]; [@c149]). Household air pollution from the use of solid fuels for cooking, although contributing to ambient ${PM}_{2.5}$, is itself a disease risk factor, independent of the surrounding outdoor pollution levels ([@c20]; [@c39]; [@c52]). Details on exposure estimation have been published previously ([@c29]; [@c131]; [@c139]). Briefly, population-weighted annual average exposure to ambient ${PM}_{2.5}$ is informed by chemical transport models and remote sensing estimates produced at $11\text{ \ kilometer\  }\left( {km} \right) \times 11\mspace{9mu}{km}$ spatial resolution with calibration to ground-level measurements (including the WHO Global Urban Ambient Air Pollution Database) ([@c131]; [@c132]; [@c139]; [@c151]). Ozone exposure is based on a fusion of multiple chemical transport model estimates and available ground monitoring data to estimate the maximum seasonal (6-month) mean of daily 8 h maximum concentrations for each grid cell ([@c26]). Household ${PM}_{2.5}$ exposure is estimated from survey data about solid cooking fuel use and measurements of ${PM}_{2.5}$ concentrations in households using solid fuels for cooking ([@c72]). Recent revisions to the GBD methods have reduced the potential for double-counting of disease burden from household and ambient air pollution in locations where both risks are present. The combined burden from the two risk factors is first estimated and then split in proportion to their contributions to exposure levels. This revision led to decreases in the burden attributable to both of these risk factors. Other air pollutants, such as nitrogen dioxide (${NO}_{2}$), may be included in future cycles of the GBD as global exposure estimates become available ([@c90]) and evidence on their role as independent risk factors accumulates. For example, a recent estimate suggests that nearly 15% of global pediatric asthma incidence was attributable to ${NO}_{2}$ ([@c1]).

Exposure estimates for a given population are then combined with cause-specific exposure--response functions to calculate the corresponding PAF ([@c139]). The exposure--response functions for ambient and household ${PM}_{2.5}$ are derived from relative risk (RR) estimates for mortality from ischemic heart disease (IHD), stroke, lung cancer, chronic obstructive pulmonary disease (COPD), lower respiratory infections (LRI), and Type II diabetes from published cohort and case--control studies. Nonlinear functions were fit to RR estimates from studies of exposure to ambient PM, household air pollution, secondhand smoke, and active smoking to characterize exposure--response functions for exposure to ${PM}_{2.5}$ across the globally observed range \[the Integrated Exposure--Response function (IER)\] ([@c23]; [@c29]). The most recent estimate based on the IER was that 4.6 (UI 4.1--5.0) million deaths were attributable to ambient and household ${PM}_{2.5}$ in 2017 ([@c139]). A novel risk function based only on epidemiological studies of ambient ${PM}_{2.5}$ suggests that the IER may underestimate the attributable burden due to differences in the shape of the risk function and additional diseases not currently included in the GBD ([@c22]; [@c93]). The risk function for ozone exposure is derived from a meta-analysis for COPD based on data from cohort studies in the United States, Canada, and the United Kingdom. Increasing exposure and the updated risk function for ozone brought the number of deaths worldwide from ambient ozone in the most recent iteration of GBD to more than 471 (UI 177--767) thousand ([@c139]).

#### Limitations and potential approaches. {#s2.1.1.1}

Although existing approaches provide critical air pollution estimates to inform policy-making, opportunities exist to facilitate targeted research---from within IHME and from the broader EH community---to improve burden estimates (see Appendix 1), particularly with respect to the response relationships in high- and low-exposure environments, the potential joint effects of exposures, the IER, differential toxicity, and source attribution.

Additional epidemiological studies in both high and low air pollution regions are needed to support estimation of relative risk across the global range of exposure and more accurately estimate TMRELs. Currently, most data come from studies conducted in high-income countries (HICs), which have lower air pollution in comparison with LMICs. The use of secondhand and active smoking data to help inform the shape of the risk curve at the high end of the ${PM}_{2.5}$ exposure range is suboptimal; cohort studies in countries at the upper end of the ambient exposure range are needed to minimize extrapolation and reliance on smoking data. As air pollution declines to even lower levels in HICs, studies of the effects of these exposures are also needed to more accurately and precisely estimate the magnitude and shape of exposure response relationships. Recently published Chinese studies ([@c165]), alternative exposure--response functions ([@c22]), and on-going research on effects of exposure to low levels of ambient air pollution by the HEI have begun to fill these needs. Further work should be encouraged and supported. Evaluation of the shape of the concentration--response relationship at low concentrations is currently an area of active research ([@c33]; [@c118]).

Additional efforts could further refine estimates of the independent and joint effects attributable to household and ambient air pollution ([@c148]; [@c147]; [@c167]). For settings with widespread household burning of solid fuels for cooking and heating, periodic exchange between household and ambient exposures results in substantial interdependence. The recent revisions to the GBD methods described above could be additionally refined by quantifying the extent of overlap between household and ambient concentrations, which would require estimates of dirty fuel use and indoor ventilation at a spatial resolution equivalent to the ambient air pollution exposure data. Data sets like the Demographic and Health Surveys (DHS) or Multiple Indicator Cluster Surveys (MICS) contain these variables or proxies, and there are established methods for producing estimates at the current resolution of GBD ${PM}_{2.5}$ estimates ([@c54]). Similar approaches could also be extended to address the overlap between exposure to ambient ${PM}_{2.5}$ and secondhand smoke, another important EH risk factor whose attributable burden is estimated using the IER approach.

The IER is a central aspect of the GBD estimations. A key assumption of the IER, and consistent with assessments conducted by the WHO ([@c157]) and the U.S. Environmental Protection Agency (U.S. EPA) ([@c150]), is that the magnitude of risk is a function of ${PM}_{2.5}$ mass alone. In other words, all particles are equally toxic on a per-unit mass basis, regardless of composition or source. Although some data suggest that ${PM}_{2.5}$ may exhibit differential toxicity depending on combustion source ([@c142]; [@c168]), there is currently insufficient evidence to move beyond the assumption of equitoxicity or create source-specific exposure--response functions ([@c97]; [@c119]; [@c140]). Further research by the broader EH community, to be leveraged by the GBD, is needed to help advance this area. Although it would require both additional evidence and methodological work to develop separate exposure--response functions for different profiles of PM and more accurately characterize mixtures across the world at sufficient resolution, a binned approach, whereby prototypical air pollution profiles are developed to represent the most common mixtures, may represent a manageable path forward. Prioritization of this effort should be based on the size of the exposed populations; for example, windblown mineral dust (e.g., from deserts) constitute a large fraction of PM in many parts of the world, Evidence is emerging to indicate that such exposures increase mortality risk; however, the relative toxicity of desert dust in comparison with other PM is uncertain ([@c80]).

An alternative approach to obtaining source-specific burden estimates is based on emissions and chemical transport modeling in which the fraction of the total particle mass attributable to a given source or sector is used to apportion exposure and, ultimately, burden ([@c30]). This approach has been applied to estimate the burden of disease attributable to major sources globally ([@c92]), including in India and China ([@c48]). Expansion of this analysis to other regions is feasible and would provide knowledge that is critical to identifying the specific sources whose control could contribute most to reductions in exposure and improvements in population health.

### Lead. {#s2.1.2}

Impacts of lead exposure on disease and death have been included in the GBD since 2003. These data have included estimates of lead's impacts on intellectual impairment (in terms of IQ decrements meeting criteria for intellectual disability, defined as an IQ below 85 points), on cardiovascular outcomes mediated through increases in blood pressure ([@c38]; [@c40]), and on the development of chronic kidney disease ([@c18]). The primary exposure metric used previously had been log-normal distributions of blood lead concentrations (B-Pb) across populations based on published studies. Since GBD 2016, ensemble modeling techniques (which synthesize the results of different analytical models) have been used to find an optimal global distribution shape by fitting a variety of distributions to the available blood lead and generating a weighted average of those distributions based on fit. GBD uses spatiotemporal Gaussian process regression (ST-GPR) to estimate B-Pb for all age groups, locations, and years. Where no data are available, estimates are informed by data from neighboring countries, and four covariates: *a*) use of leaded gasoline, *b*) numbers of two- and four-wheeled vehicles per capita, *c*) proportion of each location's population living in an urban area, and *d*) the sociodemographic index ([@c75], <http://www.healthdata.org/taxonomy/glossary/socio-demographic-index-sdi>) of the location ([@c139]). Data from primarily urban or rural locations (these data did not reflect the nationwide urban/rural distribution) were adjusted to more accurately reflect the expected national-level mean B-Pb levels, using the country's urbanicity as a covariate when estimating the adjustment. The GBD currently uses a B-Pb TMREL of $2.0\;\mu g/\text{dL}$.

The risk of intellectual disability associated with lead exposure is based on a pooled analysis of exposure--IQ decrement relationships in which losses of IQ points are converted into estimated numbers of cases of intellectual disability. Intellectual disability is classified into five levels of severity and associated disability weights (DW) are assigned: borderline (IQ 70 to 85; $\text{DW} = 0.011$), mild (IQ 50 to 69; $\text{DW} = 0.043$), moderate (IQ 35 to 49; $\text{DW} = 0.1$), severe (20 to 34; $\text{DW} = 0.16$), and profound (IQ 0 to 19; $\text{DW} = 0.2$).

The association between lead and blood pressure was initially based on meta-analyses involving large cross-sectional studies of lead and blood pressure, such as the U.S. Second National Health and Nutrition Examination Survey (NHANES II). The distribution of population B-Pbs linked to increased blood pressure was then combined with the relative risk for each blood pressure level to calculate the attributable fraction of cardiovascular disease (CVD) attributable to lead. These approaches were modified for GBD 2010 to estimate the association between bone lead levels and CVD outcomes as meditated through increases in systolic blood pressure. This modification was based on recent research demonstrating that bone lead levels, an indicator of exposure accumulated over decades that can now be measured noninvasively using K-X-ray fluorescence, are better than B-Pb at predicting CVD and other adult health outcomes ([@c110]) ([@c67]). Because population data on bone lead levels were available for only a few countries, bone lead levels were calculated by estimating secular trends in blood lead levels in each geography, integrating blood lead levels over time to generate a cumulative blood lead index (CBLI) metric, and applying an empirically derived factor to convert CBLI into bone lead levels ([@c68]). National and subnational data on blood lead levels are available in most countries, but many, particularly in Africa and Central Asia, continue to lack data (see [Figure 2](#f2){ref-type="fig"}).

![Map of unique country, source, and years of data on blood lead levels for the Global Burden of Disease Study (GBD) ([@c139]).](ehp-127-105001-g002){#f2}

The most recent iteration of the GBD has estimated that global lead exposure is responsible for 2.5 million DALYs from intellectual disability, 1.3 million DALYs from chronic kidney disease, and 20.6 million DALYs from CVD ([@c139]).

#### Limitations and potential approaches. {#s2.1.2.1}

Despite its expansion to include full and borderline intellectual disability, the DALY-based GBD accounts for only a subset of the intellectual impairment due to lead. Thus, whereas GBD calculates incremental loss of IQ from lead exposure beginning at a TMREL of $2\;\mu g/\text{dL}$ ([@c139]), contributions to DALYs are counted only for those individuals whose loss of IQ results in an IQ score below 85. However, as discussed recently by Bellinger ([@c13]), decrements in IQ across the entire distribution result in reduced economic productivity, lowered educational potential, and diminished well-being. In addition, when the process of assigning DWs within the GBD Study changed in 2010, the weights for intellectual disability decreased across the board, with, for example, the disability weight associated with mild impairment (IQ 50--69) downgraded from 0.29 to, as noted above, 0.043, an 85% reduction ([@c156]). This decrease may reflect discordance with respect to definitions of health and perspectives on whether intellectual impairment should be considered a disease.

How might GBD methods be modified to better capture the full impact of lead exposure on individual and societal health (Appendix 1)? It could be argued that any approach should consider the extent to which exposure limits an individual's educational, occupational, and social potential throughout life ([@c13]). Because these outcomes extend beyond traditional (medically based) notions of health and disease, an alternative method would be to use a human capital approach ([@c12]), which assigns monetary value to direct and indirect costs to individuals and society due to adverse outcomes, including but not limited to health. IHME has recently produced estimates of measured and expected human capital across the globe ([@c43]; [@c95]), through the creation of an index that integrates data on educational attainment (average years of education), education quality or learning (test scores), functional health (conditions linked to productivity, including poor growth, anemia, cognitive impairment, sensory impairments, certain common infectious diseases), probability of survival to age 5, and of survival from age 20 to age 64. Using this approach, the impact of lead could be applied to educational attainment and learning, given the substantial literature linking IQ to years of schooling and extensive research documenting associations between blood lead and standardized test scores ([@c5]; [@c17]; [@c99]; [@c102]; [@c104]; [@c170]). Alternatively, a hybrid approach could build on the existing GBD framework, quantifying the subclinical effects of developmental neurotoxicants and then assigning a monetary value to these effects. This strategy has been used to quantify the economic effects of population exposures to lead ([@c58]) and EDCs ([@c145]). Monetary values could be based on the Value of a Life Year (VOLY) ([@c32]), adjusted for purchasing-power parity (PPP) ([@c141]).

GBD estimates of the burden of CVD attributable to lead currently include the effects of lead on CVD only as they are mediated through blood pressure, with a threshold for effects beginning at B-Pbs of $5\;\mu g/\text{dL}$. However, a recent study using updated NHANES data demonstrated that an increase in B-Pbs from $1.0\;\mu g/\text{dL}$ to $6.7\;\mu g/\text{dL}$ was associated with an increase in all-cause mortality even after adjusting for blood pressure, with effect magnitudes several multiples greater than current GBD estimates ([@c89]). Similarly, a community-based prospective study of men in Boston, Massachusetts, found that even after adjusting for hypertension and other covariates, cumulative lead was associated with increased risk of CVD mortality ([@c155]). That lead likely has a direct effect on the cardiovascular system apart from effects on blood pressure is supported by numerous mechanistic studies demonstrating direct effects on heart muscle function, atherosclerosis, and the heart's conduction system ([@c109]). These findings suggest that the GBD may need to additionally account for evidence indicating that lead's effects on CVD are exerted directly, as well as through blood pressure.

The current TMREL of $2.0\;\mu g/\text{dL}$ should also be reconsidered. Research suggests that preindustrial B-Pb levels were likely well below $1\;\mu g/\text{dL}$ ([@c41]; [@c115]; [@c135]). Mean B-Pb levels in some populations have recently declined to below $1\;\mu g/\text{dL}$: For example, the latest published B-Pb levels among participants of the U.S. NHANES showed a mean level of $0.84\;\mu g/\text{dL}$ in the period 2013--2014 ([@c146]). In addition, the most recent research on B-Pb--IQ and B-Pb--CVD relationships demonstrates a slope that is steepest and begins at the lowest measurable levels (down to 1 or $2\;\mu g/\text{dL}$) ([@c37]; [@c69]; [@c82]; [@c88]; [@c129]; [@c154]). Lowering the TMREL from 2 to $1\;\mu g/\text{dL}$ therefore deserves serious consideration.

Finally, despite being one of the most studied EH risk factors, B-Pb data are sparse or absent in dozens of countries, particularly in Africa and Asia, where development and industrialization are occurring rapidly ([Figure 2](#f2){ref-type="fig"}). Although current exposure estimation methods are laudable, the potential exists to further expand the consortium of GBD collaborators to include researchers with unpublished data \[such as national surveillance data on over 25,000 blood lead levels in China ([@c164])\] and researchers who could add B-Pb measurement to existing or future population-based surveys. In the meantime, additional strategies could be adopted to improve B-Pb estimates.

Methods for Grading Evidence and Exposure Assessment, and Prioritizing EH Risk Factors {#s2.2}
--------------------------------------------------------------------------------------

Many well-established EH risk-outcome pairs are not included in the GBD. Examples include methylmercury and intellectual disability ([@c57]; [@c144]), nitrogen dioxide and asthma ([@c1]; [@c6]), and ${PM}_{2.5}$ and low birth weight ([@c31]; [@c42]). Although a main factor in the GBD's success is its rigor, impartiality, and standardization for establishing new risk--outcome pairs, there are challenges associated with incorporating new EH risk factors, as well as general limitations inherent in the GBD, that require consideration. Critical among the latter is the practical reality that the process of adding a new risk--outcome pair to the GBD is typically labor-intensive and thus undertaken only if the additional necessary resources are available. By contrast, the scope of pollution is enormous; Rusch and Hare ([@c126]) estimated that there are 25,000--84,000 chemicals in commerce in the United States ([@c126]). A further issue, as noted earlier, is that most EH risk--outcome pairs cannot be assessed by RCTs, thereby placing a stronger emphasis on the results of observational studies and also raising the issue of whether evidence from animal and *in vitro* studies deserve consideration in the GBD.

### Nomination process for EH risk factors. {#s2.2.3}

The current process for including new risk--outcome pairs is based on input from collaborators, followed by considering available exposure information, systematic reviews, and evidence scoring, and then approval from the GBD Scientific Council ([@c74]). With the creation of the GBD-PHI, we propose forming an EH Risk Factors Nomination Working Group (EH Working Group) to work in partnership with the GBD to ensure a systematic process for considering data to support the inclusion of new EH risk--outcome pairs and updated information (including new disease linkages) for existing risk factors. This group would be responsible for reviewing literature on EH exposures and risk--outcome pairs and nominating selected pairs for consideration. As a first step, the EH Working Group could identify candidates from existing classifications or listings from authoritative bodies. Examples include International Agency for Research on Cancer (IARC) monographs, the European Chemicals Agency (ECHA) Candidate List of substances of very high concern, the National Toxicology Program (NTP) Office of Health Assessment and Translation (OHAT) reports, California's Proposition 65 listings, U.S. EPA's Integrated Risk Information System (IRIS) reports, and Project TENDR's consensus statement ([@c14]). We recommend prioritizing new risk factors based on strength of evidence of causality with one or more health outcomes, the size of exposed populations, the feasibility of global exposure estimation, and predicted trends in exposures and relevant diseases. Linking an existing risk factor, for which the GBD already has exposure information, to a new disease is easier and may be a more practical starting point with respect to EH expansion. [Table 2](#t2){ref-type="table"} depicts a nonexhaustive list of risk factor--disease pairs that may be ready for consideration based on the criteria above.

###### 

Suggested examples of risk/outcome pairs for consideration by the Global Burden of Disease Study (GBD).[^*a*^](#TF2){ref-type="table-fn"}

Table 2 lists risk factors in the first column; the corresponding outcomes and whether global exposure assessment is available or feasible for risk factors are listed in the other columns.

  Risk factor                                                            Outcome[^*b*^](#TF3){ref-type="table-fn"}                                                                Global exposure assessment available/feasible for risk factor?
  ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Air pollution (${PM}_{2.5}$, ozone, ${NO}_{2}$)                        Dementia ([@c120])                                                                                       Yes (currently in GBD) ([@c139])
  Intellectual disability ([@c14]; [@c28])                                                                                                                                        
  [\*](#TF4){ref-type="table-fn"}Low birth weight ([@c31]; [@c42])                                                                                                                
  [\*](#TF4){ref-type="table-fn"}Hypertension ([@c19])                                                                                                                            
  [\*](#TF4){ref-type="table-fn"}Asthma ([@c1]; [@c6]; [@c59]; [@c81])                                                                                                            
  Arsenic (nonoccupational)                                              Intellectual disability ([@c56])                                                                         Regional assessments have been conducted (e.g., Bangladesh ([@c134]); Latin America ([@c21])
  Lung cancer ([@c71])                                                   Needs to be scaled and modeled for global coverage                                                       
  Bladder cancer ([@c71])                                                                                                                                                         
  Skin cancer ([@c71])                                                                                                                                                            
  Lead                                                                   [\*](#TF4){ref-type="table-fn"}Cardiovascular disease (direct effects; *low-level exposures*) ([@c89])   Yes (currently in GBD) ([@c139])
  Methylmercury                                                          Intellectual disability ([@c56])                                                                         Yes ([@c11])
  Organophosphate pesticides                                             Intellectual disability ([@c56])                                                                         Included in national and regional biomonitoring ([@c25])
  Needs to be scaled and modeled for global coverage                                                                                                                              
  Phthalates                                                             BMI ([@c8]; [@c91])                                                                                      Included in national and regional biomonitoring ([@c25])
  Diabetes ([@c8]; [@c91])                                               Needs to be scaled and modeled for global coverage                                                       
  Infertility ([@c8]; [@c61])                                                                                                                                                     
  Per- and polyfluoroalkyl substances                                    BMI ([@c98])                                                                                             Included in national and regional biomonitoring ([@c25])
  Low birth weight ([@c77])                                              Needs to be scaled and modeled for global coverage                                                       
  Polybrominated diphenyl ethers                                         Intellectual disability ([@c56])                                                                         Included in national and regional biomonitoring ([@c25])
  Needs to be scaled and modeled for global coverage                                                                                                                              
  Polychlorinated biphenyls                                              Intellectual disability ([@c56])                                                                         Included in national and regional biomonitoring ([@c25])
  Melanoma ([@c3])                                                       Needs to be scaled and modeled for global coverage                                                       

Not comprehensive; selected examples only.

Some of the outcomes listed here (e.g., hypertension, BMI, low birth weight) are actually risk factors for outcomes in the GBD rather than outcomes themselves. Thus, future modeling would be conducted as mediation analyses, evaluating how, for example, low birth weight mediates the association between an EH exposure and an established GBD outcome.

Indicates consideration for inclusion in GBD2019.

### Causality and evidence scoring criteria. {#s2.2.4}

After nomination, EH risk--outcome pairs would be subject to the same criteria used for other risk--outcome pairs in the GBD. To date, GBD has used the World Cancer Research Fund evidence grading system ([@c163]), with "convincing" or "probable" evidence as a requirement for inclusion. Causal criteria include consideration of study design, relative risk, dose--response relationship, biological plausibility, and analogy ([@c139]). GBD's current system gives greatest weight to RCTs, which, for ethical and practical reasons, are only possible for very few EH exposures (e.g., clean cook stoves, energy interventions to reduce household air pollution) ([@c137]; [@c4]). Observational studies are the primary epidemiologic method for EH. Careful design can mitigate many concerns about residual confounding even in the absence of *a priori* randomization, such as the application of causal modeling techniques ([@c125]; [@c169]). In addition, the U.S. NTP and others have adapted systematic review frameworks to assess hazards that, in addition to epidemiological studies, consider a range of experimental animal and mechanistic data to reach conclusions ([@c123]; [@c160]). We see opportunities for collaboration between IHME and NTP to advance the use of systematic review in environmental health. GBD is in the process of implementing a quantitative data-driven evidence scoring approach that will likely yield different categories of evidence for risk--outcome pairs, leading to a series of burden estimates based on different levels of evidence.

Finally, given concerns about the influence of funding on study findings ([@c16]; [@c45]; [@c50]; [@c70]; [@c101]), any assessment of data quality and causality in EH should include consideration of conflict of interest. The recently developed Navigation Guide systematic review method includes "conflict of interest" as a domain in its risk of bias assessment ([@c161]), and we would encourage a similar approach for the GBD.

### Global exposure assessment. {#s2.2.5}

To best inform the GBD, exposure measurements need to capture variability by sex, age, seasonality, and national/subnational geography, so that exposure models can calculate age--sex, regional, and time-of-year--specific estimates of mortality or DALYs. Although it is challenging to estimate exposure to many environmental risk factors, air pollution has fairly robust exposure estimates worldwide. In the most recent iteration of the GBD, data coverage for subnational geographies was as follows: ozone pollution data: 100% (although some of the ozone data are based on chemical transport models); ambient PM: 58%; and household air pollution from solid fuels: 85.5% ([@c139]). Additional tools that could be leveraged in the future include regional emissions inventories ([@c83]), low-cost samplers and sensors ([@c9]; [@c111]; [@c112]), and the use of high-resolution satellite imagery ([@c47]).

Estimating global exposure to lead is more difficult, however, and emblematic of the challenges presented by many other EH exposures. Population exposure to lead in the mid- to late-20th century was dominated by inhalation of leaded gasoline, and B-Pb was accurately modeled using data on measured air lead levels, sales of leaded gasoline, and traffic density. However, the current predominant sources of lead exposures are mostly due to contamination of food, water, dust, and soil, which are more challenging to model. Thus, it is necessary to rely on population-specific B-Pb. However, as noted earlier in the lead case study, in the most recent iteration of the GBD, B-Pb data were lacking for many countries in Africa and central Asia; moreover, global data were available for only 39.6% of the subnational geographies ([@c44]), forcing the GBD to rely on data derived from exposure to leaded gasoline, likely leading to biased estimates where other routes and sources of exposure are not considered (i.e., food, water, occupational exposures). An example is India, which phased lead out of gasoline in 2000, but recent data indicate continuing high levels of B-Pb in children ([@c27]).

Going forward, innovations will be needed on multiple levels to address the challenge of assessing global exposures for new pollutants being considered for entry into the GBD, with particular challenges posed by the lack of data for most exposures of concern, especially in LMICs. Some of the innovations could be technological, with the development of new, low-cost tools for measuring pollutants in biological as well as environmental media. Other innovations may involve diversifying sources of data. For example, with respect to methylmercury, arsenic, trace metals, pesticides, PBDEs, and other exposures found to occur mainly via diet ([@c128]; [@c159]; [@c166]), extrapolations could be made from market-basket surveys ([@c122]) and drinking water assessments ([@c153]). Computational approaches should also be considered. A 2016 U.S. National Academies of Sciences report detailed the promise of modeling approaches that can aggregate information on chemical properties and emission sources with environmental fate and transport characteristics to predict near- and far-field human exposures to a large number of pollutants ([@c107]).

Perhaps the most important innovation that will be key to advancing assessment of global pollutant exposures for the GBD will be soliciting the involvement of subject-matter experts around the world (and training them where few exist). The GBD project currently involves more than 3,600 researchers in more than 145 countries. However, few of the researchers are exposure or EH scientists; and of these exposure or EH experts, there is limited representation among LMICs. Efforts have already started in this area through the promotion of GBD symposia in relevant professional societies, such as the International Society for Environmental Epidemiology (ISEE) and the International Society of Exposure Science (ISES). In addition, Landrigan et al. recently created the Global Pollution Observatory on Pollution and Health as a consortium to collect, archive, and analyze data on pollution and disease worldwide ([@c87]). Such an effort will meet its promise only with the involvement of LMIC-based researchers, particularly because the Lancet Commission on Pollution and Health estimated that 92% of pollution-related mortality occurs in these regions ([@c86]). The cultivation of regional expertise and engagement in this initiative will be critical not only in terms of gathering data relevant to exposures, but also in terms of providing interpretation of the data in relation to nuances such as local behaviors, industrial and social trends, and national and regional chemicals management policies. Efforts to increase EH capacity of individuals and institutions across LMICs, as well as to strengthen and help sustain regional and global networks, continue to be promoted through efforts like Fogarty International Center's GEOHealth program and Canada's IDRC EcoHealth Chairs program.

A related issue in the field of exposure is the estimation of the TRMEL. As noted earlier, a critical step in calculating the attributable burden for each risk--outcome pair is the estimation of the exposure counterfactual or TMREL. Relatively small changes in the TMREL can result in relatively large changes in the PAF, underscoring the importance of making accurate estimations. However, this can be challenging for naturally occurring pollutants, such as arsenic, or for others that have imbued the ecosystem and entered the food chain in various ways, such as mercury. Establishing a TMREL for climate-related risk factors, such as heat, will also be challenging and an area for discussion in the coming years.

Examples of Candidate EH Risk Factors for Inclusion in the GBD {#s2.3}
--------------------------------------------------------------

### Neurotoxicants. {#s2.3.6}

Lead is the best-studied neurodevelopmental toxicant, but there are others for which there is strong evidence and widespread exposure. Evidence is strong or rapidly accumulating for the impact of methylmercury, arsenic, polychlorinated biphenyls, polybrominated diethyl esters (PBDEs), organophosphate pesticides, and particulate air pollution on diminished cognitive function, shortened attention span, and behavioral disruption; each has been subject to systematic or similarly in-depth reviews ([@c14]; [@c28]; [@c36]; [@c57]; [@c78]; [@c85]; [@c94]; [@c116]; [@c133]; [@c143]). Extensive use of these chemicals has resulted in pervasive human exposure, and virtually everyone has detectable levels of multiple neurotoxicants in their bodies ([@c25]). Moreover, diminished cognitive function is associated with even the lowest measurable concentrations for many of these neurotoxicants ([@c57]).

The health impacts of exposures to these other neurotoxicants should be quantified to illustrate the benefits of exposure reductions. Especially robust dose-response and exposure data have been developed for methylmercury, for example ([@c11]; [@c78]). IHME could evaluate the effects of these exposures using the newly developed human capital index; a similar analysis was recently published for an extended group of environmental chemicals ([@c55]). However, despite the documented neurobehavioral effects of these risk factors, limited exposure data present a challenge in developing global exposure models. For others, data may not be yet sufficient to meet the GBD\'s criteria for causality. Due to these limitations, none of these other neurotoxicants are currently included in the GBD. Inclusion of these and other chemicals would serve to add urgency to the need to address their public health impacts. A phased approach to considering other neurotoxic agents could begin with an evidence-scoping phase to identify the information gaps for the major neurotoxicants listed above (e.g., the lack of exposure data or the lack of evidence to support causality). In subsequent steps, research efforts could be directed to fill the key data gaps, and individual risk--outcome pairs could be addressed in subsequent GBD reviews.

### Endocrine-disrupting chemicals (EDCs). {#s2.3.7}

Growing evidence documents the link between EDC exposure and numerous adverse outcomes, including hormone-related cancers, infertility, reproductive dysfunction, birth defects, obesity, diabetes, and neurobehavioral disruptions ([@c15]; [@c34]; [@c53]). Examples of specific risk--outcome pairs, among many, include bisphenol A and childhood obesity, and benzyl-phthalates and butyl-phthalates and male infertility ([@c8]). Prior work external to the GBD highlights the enormous economic burden due to these exposures in the United States and the European Union: $\$ 340\text{ \ billion}$ and $\$ 217\text{ \ billion}$, respectively ([@c8]; [@c145]). Integration of these efforts into future iterations of the GBD would result in the expansion of EDC burden estimates to cover LMICs. This expansion is particularly important because LMICs are predicted to become the chief producers of synthetic chemicals, many of which are EDCs, by 2030 ([@c113]); increased utilization and consumption in those countries are also anticipated. Additionally, given the worldwide visibility of the GBD, estimates for EDCs would provide further visibility to the concern regarding these ubiquitous exposures.

There are several challenges to incorporating EDCs into the GBD; we highlight selected examples here. First, there is disagreement about the definition and criteria for an *adverse effect* in the context of the endocrine system ([@c162]; [@c176]; [@c175]). These debates are in some ways analogous to the discussion of lead and IQ decrements, because some EDC-related changes may be considered adverse even without reaching thresholds based on clinical constructs for apical end points. Second, much of the data on EDCs are generated from *in vitro* and *in vivo* studies; in addition, methods for integration of this evidence into the GBD decision-making process are not well defined, despite this being an active area of research ([@c108]; [@c152]). Additionally, because there is still much uncertainty about the health effects of some EDCs, their incorporation into the GBD may prompt the need to expand the estimation process to allow for differing tiers of certainty.

Another challenge is obtaining robust exposure estimates for EDCs across the globe. Nevertheless, even with imperfect exposure measurements and uncertainties in risk functions, the addition of these and other EH risk factors is crucial given the large burden estimations developed by other groups as cited above; an important aspect is that, as stated in the GBD Protocol, "an uncertain estimate, even when data are sparse or not available, is preferable to no estimate because no estimate is often taken to mean no health loss from that condition" ([@c73]). Although some degree of uncertainty is acceptable, we also recognize that data to inform models must be adequate to produce estimates that are credible and provide enough certainty to be useful to the public health community and policy makers. To this end, we encourage further research to evaluate EDC exposure levels around the world.

Special Cases of Climate and Climate Change {#s2.4}
-------------------------------------------

Climate change presents a challenge for the GBD, as it cannot easily be captured as a discrete exposure but is instead represented by multiple hydrometeorological indicators. Unlike other exposures, there is no theoretical minimum future climate change exposure that can be attained, and it is unclear what the baseline level for climate risk should be, given its unique status as a constantly changing global system. Climate change--related exposures will continue to increase in the next few decades, no matter the extent of reductions of greenhouse gas emissions. For present and future climate-related risks, the risk--outcome pathways (e.g., undernutrition, malaria, diarrheal disease, and injury) are often indirect, making attribution challenging.

Because climate-related health impacts are closely tied with local mediating factors, the same hydrometeorological events affected by climate change may have very different consequences within and between locations and populations, making it challenging to extrapolate health outcomes in low-income settings from studies conducted in higher-income settings, an issue common to many environmental exposures. Although researchers have considerable experience with projecting the magnitude and pattern of certain climate-sensitive health outcomes (such as mortality associated with heat or malaria) at local to international geographic scales ([@c35]), projecting other climate-sensitive health outcomes, such as the disease burden associated with climate-driven conflict or migration, is more challenging. GBD incorporated a limited set of climate risks in its 2000 analysis ([@c37]) but has opted not to make attributions of climate risk in recent reports, in part because of the aforementioned challenges. Nevertheless, given the importance of estimating the disease burden from climate-related risk factors and demand from health ministries for such estimates, the GBD team has taken a first step to robustly estimating health impacts associated with climate change by beginning to incorporate risks related to suboptimal ambient temperature exposure, a process that is currently ongoing and might be expanded to include scenario-based projections.

A variety of climate-sensitive risk--outcome pair additions and modifications might be considered in future iterations of the GBD. For example, there is a well-documented association between ambient temperature and ground-level ozone formation, as well as growing evidence for temperature-driven increases in ${PM}_{2.5}$ in drier regions, both of which are associated with increased morbidity and mortality ([@c2]; [@c114]). In addition, higher carbon dioxide (${CO}_{2}$) concentrations are associated with reduced micronutrients, protein, and B vitamins in staple crops, particularly wheat and rice ([@c173]). These trends may exacerbate micronutrient deficiencies that are associated with a variety of physical and cognitive ailments ([@c10]). Other risk--outcome pairs could be incorporated into future iterations of the GBD, including those associated with risks, such as precipitation changes, and outcomes, such as injuries, diarrheal disease, undernutrition, cardiovascular disease, and mental health, among others ([@c138]). Moreover, risks currently in the GBD, such as extreme weather events, will likely require attribution to climate change as the science becomes more robust. In addition, climate-related risk factors affect upstream drivers of health and welfare outcomes, including economic productivity, fertility, migration, and governance capacity. Altogether, these interconnected relationships present potentially far-reaching consequences for global health.

### Modeling challenges: Aeroallergens and asthma as an example. {#s2.4.8}

Many diseases included in the GBD have some climate sensitivity that is not currently captured, sometimes as a result of data and modeling limitations. Multiple risk factors map to each outcome, and data are not of sufficient quality or spatiotemporal resolution to characterize the attributable burdens associated with each individual driver. An example is asthma associated with aeroallergens. Climate change is increasing allergenic pollen exposure and thus could increase the burden of allergic disease. Aeroallergens are associated with allergic rhinitis, allergic asthma, and other conditions, and both allergic asthma development and asthma exacerbations are driven by aeroallergen exposure. Climate change has increased the length of the pollen season for certain allergens in North America above 44°N by 2 to 4 wk since 1995 ([@c174]). However, relatively few studies have documented the dose--response relationships between pollen seasonality or magnitude and specific health outcomes. One study suggests moderate and severe climate change could increase oak pollen season length and associated asthma emergency department visits in the eastern United States by 5% and 10%, respectively, by 2090, translating into tens of thousands of pollen-related asthma emergency department visits ([@c7]). Although allergic disease is not included as a specific outcome in the GBD, asthma caused 23.7 million DALYs in 2016, up to half of which may be attributed to allergies ([@c46]; [@c117]). Thus, the DALY burden of climate-induced changes in pollen-season length and intensity could be substantial. Nevertheless, attributing changes in allergy burden to climate change is challenging, given limitations in risk factor (i.e., aeroallergen) and outcome (i.e., allergic asthma) data, as well as a paucity of robust studies that might support dose--response characterization for this risk--outcome pair. This uncertainty highlights a need for funders to the support collection of data to facilitate modeling of this climate-sensitive outcome.

### Climate projections. {#s2.4.9}

An important goal relates to modeling the possible consequences of climate change on the future burden of climate-sensitive health outcomes. This modeling is particularly important for decision-makers because the consequences of climate change, such as exposure to airborne PM from wildfires and soil dust, are likely to increase considerably in the coming decades. Modeling needs to consider not just changes in climate-related hazards and population exposure to these hazards, but also factors that affect sensitivity to the exposures and the capacity to manage changing exposures, such as changes in population distribution and investment in building climate-resilient health systems ([@c130]).

The GBD is currently developing scenario-based forecasting models for disease burdens, which will require years of incremental improvements ([@c43]). The current iteration of this forecasting model does not explore the health effects of climate change, although we believe this framework can be extended to incorporate these impacts. Such an extension will likely require incorporating feedbacks from climate shocks onto sociodemographic drivers, estimating the health impacts associated with adaptation and mitigation measures, as well as exploring potential health impacts associated with events lacking in historical precedents, such as sea-level rise.

To facilitate model development, we suggest convening a broad range of climate and health experts in the natural and social sciences to advise this work, including experts researching thermal extremes, vector-borne disease, climate and pollution, undernutrition, sea-level rise, migration, and other relevant subject areas. These experts would help elucidate the global burden of disease related to climate change in four ways: *a*) by estimating the climate change--attributable impact on climate-sensitive health outcomes that are in the GBD but do not disaggregate upstream drivers such as climate change (e.g., malaria and waterborne diseases); *b*) by tracking changes over time in dose--response relationships for climate-sensitive risk--outcome pairs and updating models accordingly; *c*) by evaluating the addition of new risk--outcome pairs to incorporate into future GBD projections as evidence builds; and *d*) by examining the impact of climate-change mitigation policies on health effects, as is currently done by GBD for policies related to the SDGs ([@c100]). Finally, GBD should seek to harmonize its forecasts with other established methods for estimating how different development scenarios, including projections of demographic and socioeconomic change, could interact with climate change to modify projected health burdens, such as the Shared Socioeconomic Pathways ([@c130]).

Conclusion {#s3}
==========

The GBD-PHI is a recently emerged virtual initiative being advanced by a community of scientists who come from a diverse array of disciplines but who are focused on the task of elucidating the true environmental footprint on the global burden of disease, disability, and impaired human capital. The ultimate aim is to provide policymakers with the informational tools for reducing and preventing these impacts as each country and region strives to meet the SDGs. As the initiative gets underway, this paper aims to highlight some of the key challenges and opportunities for enhancing the characterization of EH risk factors in the GBD (Appendix 1). Although air pollution and lead are already included in these analyses, the limitations highlighted above suggest that several specific enhancements could further improve the accuracy and utility of these globally influential estimates.

Collaboration from within the EH community, including efforts to leverage existing research, can expedite and facilitate the incorporation of new risk--outcome pairs. Ancillary studies producing global or region-specific burden estimates for new EH risk--outcome pairs using methods closely aligned with the GBD can provide the scientific rationale for inclusion. Investigators who have developed a set of global exposure estimates can combine these with either published or de novo meta-analytic concentration--response summaries and GBD baseline disease incidence information to develop proof-of-concept global disease burden estimates. An example is the recent quantification of ${NO}_{2}$-attributable pediatric asthma ([@c1]). It would be important for analyses to align exposure--response functions with the specific outcome classifications currently included in the GBD or to develop methods to link GBD outcomes to other outcomes used in epidemiological studies. Further, ancillary studies may provide more in-depth insight into the role of pollution sources or the potential benefits of various policy scenarios on disease burden, as has become common with respect to air pollution ([@c49]; [@c171]; [@c172]).

To generate quantitative estimates for the GBD, adequate data must exist to credibly estimate exposure to the risk factor for all countries and timeframes included. Such data do not currently exist for most EH risk factors. We predict that the proliferation of new technologies and the sources of "Big Data" on population health scales will improve exposure assessment to support the addition of new EH risk--outcome pairs in future iterations of the GBD, and we encourage research to accelerate this process ([@c65]). The GBD-PHI can support progress by building collaborations with EH colleagues conducting such research and through partnerships with, among others, the U.S. National Institute of Environmental Health Sciences (NIEHS), the WHO, the United Nations Environment Programme (UNEP), the Intergovernmental Panel on Climate Change (IPCC), ISEE, ISES, the Global Observatory on Pollution and Health, and the HEI. GBD scientists can play a role by highlighting key gaps in exposure data to inform relevant research.

GBD estimates are influential at the local, subnational, national, and international levels, and they help all governments evaluate comparative risks and make evidence-based decisions to improve public health. These estimates have an especially important role in LMICs, which often experience particularly high burdens from EH exposures, and for countries that lack the resources to estimate risk exposure and risk-attributable burden internally. As the GBD expands its breadth with regard to EH risk--outcome pairs, its results can facilitate expanded economic analyses and policy assessments. Further consideration of the range of effects on human capital, including both education and health, is crucial. Only with adequate quantification of the adverse impacts of a broad range of EH exposures will governments and policy makers be positioned to make well-informed decisions to appropriately allocate resources for public health. These efforts, which will be further described in a follow-up manuscript, are particularly important for reaching ambitious global targets, such as the SDGs, and for more accurate quantification of the risks and benefits of pollution mitigation and prevention efforts.
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